[go: up one dir, main page]

MX2009010675A - Formulaciones farmaceuticas de moleculas de la hormona liberadora de la hormona delcrecimiento humana. - Google Patents

Formulaciones farmaceuticas de moleculas de la hormona liberadora de la hormona delcrecimiento humana.

Info

Publication number
MX2009010675A
MX2009010675A MX2009010675A MX2009010675A MX2009010675A MX 2009010675 A MX2009010675 A MX 2009010675A MX 2009010675 A MX2009010675 A MX 2009010675A MX 2009010675 A MX2009010675 A MX 2009010675A MX 2009010675 A MX2009010675 A MX 2009010675A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
ghrh
formulation
molecules
disclosed
Prior art date
Application number
MX2009010675A
Other languages
English (en)
Inventor
Helen Loughrey
Byeong Chang
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of MX2009010675A publication Critical patent/MX2009010675A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen formulaciones farmacéuticas sólidas y líquidas estabilizadas que comprenden moléculas de GHRH como ingrediente activo y más particularmente análogos de GHRH que incluyen [trans-3-hexenoil]hGHRH (1-44) amida. La formulación comprende un tensoactivo aniónico y un azúcar no reductor, y tiene un pH de aproximadamente 4.0 a aproximadamente 7.5. También se describe el uso de la formulación para el tratamiento de varias afecciones, métodos para preparar la formulación, así como también equipos que la contienen.
MX2009010675A 2007-04-04 2008-04-04 Formulaciones farmaceuticas de moleculas de la hormona liberadora de la hormona delcrecimiento humana. MX2009010675A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90998507P 2007-04-04 2007-04-04
PCT/CA2008/000637 WO2008122118A1 (en) 2007-04-04 2008-04-04 Pharmaceutical formulations of ghrh molecules

Publications (1)

Publication Number Publication Date
MX2009010675A true MX2009010675A (es) 2009-10-23

Family

ID=39827484

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010675A MX2009010675A (es) 2007-04-04 2008-04-04 Formulaciones farmaceuticas de moleculas de la hormona liberadora de la hormona delcrecimiento humana.

Country Status (13)

Country Link
US (1) US20080249017A1 (es)
EP (1) EP2142207A4 (es)
JP (1) JP2010523501A (es)
KR (1) KR20090130044A (es)
CN (1) CN101678083A (es)
AU (1) AU2008235215A1 (es)
BR (1) BRPI0809441A2 (es)
CA (1) CA2680329A1 (es)
IL (1) IL200810A0 (es)
MX (1) MX2009010675A (es)
RU (1) RU2009140731A (es)
WO (1) WO2008122118A1 (es)
ZA (1) ZA200906179B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE552032T1 (de) 2005-07-14 2012-04-15 Lithera Inc Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
GB2443287B (en) * 2006-10-17 2009-05-27 Lipothera Inc Methods, compositions and formulations for the treatment of thyroid eye disease
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
EP2523667A4 (en) * 2010-01-15 2014-04-02 Lithera Inc LYOPHILIZED CAKE FORMULATIONS
JP5582983B2 (ja) * 2010-11-24 2014-09-03 楠本化成株式会社 水系沈降防止剤
MX2013005873A (es) 2010-11-24 2013-08-07 Lithera Inc Formulaciones monoterapeuticas de agonistas beta selectivo, lipofilo y de accion prolongada y procedimientos para el tratamiento cosmetico de adiposidad y abultamiento del contorno.
JP2016027003A (ja) * 2012-11-20 2016-02-18 大蔵製薬株式会社 長期間安定なオランザピンの水性医薬製剤
US8871713B2 (en) * 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
KR20210145226A (ko) 2019-03-29 2021-12-01 더 제너럴 하스피탈 코포레이션 간 질환의 치료에서 사용하기 위한 ghrh 또는 이의 유사체
US20230270865A1 (en) * 2020-07-05 2023-08-31 Theratechnologies Inc. Low-dose pharmaceutical compositions of ghrh analogs and uses thereof
WO2024133908A1 (en) * 2022-12-23 2024-06-27 Syna Therapeutics, S.L. Stable pharmaceutical compositions comprising romiplostim

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137872A (en) * 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5876992A (en) * 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
EP0880969A1 (en) * 1997-05-28 1998-12-02 Applied Research Systems ARS Holdings N.V. Pharmaceutical compositions of peptides having low solubility in physiological medium
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
ATE355856T1 (de) * 1998-07-30 2007-03-15 Point Biomedical Corp Neuer wirkstoffträger für die gefriertrocknung von wässrigen suspensionen von mikropartikeln
EP1064934A1 (en) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
WO2002028437A1 (en) * 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
WO2003068805A2 (en) * 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
RU2005111253A (ru) * 2002-09-18 2005-11-20 Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) Аналоги ghrh
WO2004105789A1 (en) * 2003-05-29 2004-12-09 Theratechnologies Inc. Grf analog compositions and their use
EP1740213B9 (en) * 2004-04-07 2012-06-13 Ares Trading S.A. Liquid growth hormone formulation
AU2005297366B2 (en) * 2004-10-20 2011-12-08 Theratechnologies Inc. GH secretagogues and uses thereof
US20060188555A1 (en) * 2005-01-21 2006-08-24 Micheal Cormier Therapeutic peptide formulations with improved stability

Also Published As

Publication number Publication date
CN101678083A (zh) 2010-03-24
KR20090130044A (ko) 2009-12-17
AU2008235215A1 (en) 2008-10-16
JP2010523501A (ja) 2010-07-15
US20080249017A1 (en) 2008-10-09
EP2142207A4 (en) 2013-01-16
WO2008122118A1 (en) 2008-10-16
CA2680329A1 (en) 2008-10-16
ZA200906179B (en) 2010-05-26
IL200810A0 (en) 2010-05-17
EP2142207A1 (en) 2010-01-13
RU2009140731A (ru) 2011-05-10
AU2008235215A2 (en) 2011-02-24
BRPI0809441A2 (pt) 2015-06-23

Similar Documents

Publication Publication Date Title
MX2009010675A (es) Formulaciones farmaceuticas de moleculas de la hormona liberadora de la hormona delcrecimiento humana.
MX2009011816A (es) Derivados de piridina.
MXPA05012678A (es) Forma cristalina del agonista del receptor adrenergico beta2.
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
NO20092998L (no) Flytende formuleringer, som danner dermal film, for frigjoring av legemidler til huden
WO2008130320A3 (en) Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
MY143795A (en) Tetrahydropyridoindole derivatives
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
WO2004100865A3 (en) New benzimidazole derivatives
WO2007052123A3 (en) Pyrazine derivatives as sodium channel modulators for the treatment of pain
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
WO2007113202A8 (en) Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists
UA86441C2 (ru) (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
EP1725536B8 (en) Imidazoline derivatives having cb1-antagonistic activity
MXPA02012889A (es) Esteres de acidos 4-alcoxi-ciclohexano-1-amino-carboxilicos y procedimiento para su obtencion.
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
UA100865C2 (ru) Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины
WO2008135830A8 (en) N- [6-amino-5- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
MX2009012712A (es) Nuevas 4-fenil-imidazol-2-tionas como inhibidores de la tirosinasa, su procedimiento de preparacion y su uso en medicina humana asi como en cosmetica.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal